News Column

Studies from Federal University Update Current Data on Lung Cancer (Encapsulation in lipid-core nanocapsules overcomes lung cancer cell resistance to...

July 30, 2014



Studies from Federal University Update Current Data on Lung Cancer (Encapsulation in lipid-core nanocapsules overcomes lung cancer cell resistance to tretinoin)

By a News Reporter-Staff News Editor at Biotech Week -- Research findings on Oncology are discussed in a new report. According to news originating from Porto Alegre, Brazil, by NewsRx correspondents, research stated, "Tretinoin is a retinoid derivative that has an antiproliferative effect on several kinds of tumours. Human lung adenocarcinoma epithelial cell lines (A549) exhibit a profound resistance to the effects of tretinoin."

Our news journalists obtained a quote from the research from Federal University, "Nanocarriers seem to be a good alternative to overcome cellular resistance to drugs. The aim of this study was to test whether tretinoin-loaded lipid-core nanocapsules exert an antitumor effect on A549 cells. A549 cells were incubated with free tretinoin (UN), blank nanocapsules (LNC) and tretinoin-loaded lipid-core nanocapsules (UN-LNC). Data from evaluation of DNA content and Annexin V binding assay by flow cytometry showed that TTN-LNC induced apoptosis and cell cycle arrest at the G1-phase while UN did not. UN-LNC showed higher cytotoxic effects than ITN on A549 cells evaluated by MTT and LIVE/DEAD cell viability assay. Gene expression profiling identified up-regulated expression of gene p21 by TTN-LNC, supporting the cell cycle arrest effect."

According to the news editors, the research concluded: "These results showed for the first time that UN-LNC are able to overcome the resistance of adenocarcinoma cell line A549 to treatment with UN by inducing apoptosis and cell cycle arrest, providing support for their use in applications in lung cancer therapy."

For more information on this research see: Encapsulation in lipid-core nanocapsules overcomes lung cancer cell resistance to tretinoin. European Journal of Pharmaceutics and Biopharmaceutics, 2014;87(1):55-63. European Journal of Pharmaceutics and Biopharmaceutics can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; European Journal of Pharmaceutics and Biopharmaceutics - www.elsevier.com/wps/product/cws_home/600120)

The news correspondents report that additional information may be obtained from E. Schultze, Univ Fed Rio Grande do Sul, Inst Quim, Dept. of Quim Organ, BR-90610000 Porto Alegre, RS, Brazil. Additional authors for this research include A. Ourique, V.C. Yurgel, K.R. Begnini, H. Thurow, P.M.M. de Leon, V.F. Campos, O.A. Dellagostin, S.R. Guterres, A.R. Pohlmann, F.K. Seixas, R.C.R. Beck and T. Collares (see also Oncology).

Keywords for this news article include: Porto Alegre, Brazil, South America, Drug Delivery Systems, Emerging Technologies, Lung Cancer, Lung Neoplasms, Nanocapsules, Nanotechnology, Oncology, Therapy

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters